Subcellular compartmentalization of protein kinases and phosphatases through their interaction with A-kinase anchoring proteins (AKAPs) provides a mechanism to control signal transduction events at specific sites within the cell. Recent findings suggest that these anchoring proteins dynamically assemble different cAMP effectors to control the cellular actions of cAMP spatially and temporally. In the heart, signaling events such as the onset of cardiac hypertrophy are influenced by muscle-specific mAKAP signaling complexes that target protein kinase A (PKA), the cAMP-responsive guanine-nucleotide exchange factor EPAC and cAMP-selective phosphodiesterase 4 (PDE4). Mediation of signaling events by AKAPs might also have a role in the control of lipolysis in adipocytes, where insulin treatment reduces the association of AKAPs with G-protein-coupled receptors. These are only two examples of how AKAPs contribute to specificity in cAMP signaling. This review will explore recent development that illustrates the role of multiprotein complexes in the regulation of cAMP signaling.
A-kinase anchoring proteins: focal points in cAMP signaling Binding of extracellular messengers to receptors on the cell surface initiates transmission of a signal via synthesis of second messengers (see Glossary) [1] . Small molecules such as cAMP are rapidly formed and diffuse into the cytosol to activate downstream effector proteins such as cyclic-nucleotide-gated (CNG) channels, guanine-nucleotide exchange proteins (EPACs) and the serine-threonine protein kinase A (PKA). This process provides a mechanism whereby extracellular stimuli can influence diverse biological processes. Conversely, signal termination is achieved because members of the phosphodiesterase (PDE) superfamily locally degrade cAMP into 5 0 -adenosine monophosphate (5 0 -AMP). A-kinase anchoring proteins (AKAPs) contribute to the specificity of cAMP signaling by targeting PKA in proximity to cAMP gradients generated by the counterbalancing activities of adenylyl cyclases and PDEs. This provides a mechanism by which cAMP regulates cellular responses to external stimuli within specific subcellular regions and for limited time intervals [2, 3] .
Here, we will focus on recent findings on the role of AKAPs in the control of cAMP gradients, which are important in widespread biological phenomena. An example of this is the assembly of a multienzyme complex by the muscle-specific mAKAP to co-ordinate cAMPeffector regulation of signaling pathways involved in cardiac hypertrophy. Similarly, it has been shown that AKAPs are involved in insulin action in adipose tissue [4] , although the AKAP that is responsible for targeting PKA to G-protein-coupled receptors in adipocytes has not been yet identified.
Dynamic cAMP gradients
To date, there are nine known members of the mammalian adenylyl cyclase family that synthesize cAMP from ATP in response to G-protein-coupled-receptor stimulation [5, 6] ( Figure 1) Second messengers: small molecules that are generated or released in the cytosol to relay a signal to the interior of the cell in reponse to an extracellular signal (e.g. cAMP).
are now being used to investigate the temporal and spatial aspects of cAMP signaling in living cells [4, [7] [8] [9] [10] [11] [12] [13] [14] [15] . Although the diffusion of cAMP has long been considered to be fast within cells, recent studies have suggested that enzymes involved in cAMP synthesis and degradation generate boundaries for cAMP diffusion [7] [8] [9] 16, 17] . Studies in HEK293 cells where rat olfactory CNG channels, which have been modified to be sensitive to cAMP, were overexpressed have illustrated that distinct cAMP signals coexist within these cells [10] . In these studies, local changes in cAMP levels were determined by fluorescent monitoring of Ca 2C influx through mutant CNG channels, whereas global cAMP changes were determined by measuring the conversion of [ [10] observed that upon prostaglandin-E1 stimulation there was a transient increase of cAMP level in proximity to the membrane, whereas total cellular cAMP rose to a sustained level. Another approach to investigate the spatial and temporal control of cAMP gradients in living cells used fluorescent resonance energy transfer (FRET) reporters with fluorescently labeled regulatory and catalytic subunits of PKA [11, 12] . These reporters have been successfully used to demonstrate that stimulation of b-adrenergic receptors in neonatal rat cardiac myocytes results in the generation of cAMP gradients [13] .
Conversely, termination of cyclic-nucleotide signaling is achieved by PDEs, a superfamily of O70 different isozymes that degrade cAMP and cyclic GMP (cGMP). Distinctive tissue distribution, subcellular compartmentalization and differential regulation of these enzymes contribute to the establishment of local cAMP gradients by limiting the diffusion of cAMP that is generated by adenylyl cyclases [18, 19] . The type-4 PDEs are a family of O16 distinct isoforms that have a conserved catalytic core. Divergence within the N-terminal region of PDE4 isoforms enables association with various proteins and, therefore, differential subcellular targeting and regulation [19] . Importantly, the PDE4D3 isozyme has been shown to be part of signaling complexes that target PKA. These two cAMPresponsive enzymes (PDE and PKA) are found in complex with a growing number of AKAPs [20, 21] , thereby enabling tight regulation of cAMP.
AKAPs: a family of proteins that target PKA AKAPs are a family of O50 anchoring proteins that, although being structurally diverse, have in common the ability to bind to and target PKA [2, 3] (Figure 2 ). PKA is a heterotetramer that consists of two catalytic (C) subunits held in an inactive conformation by a regulatory (R) subunit dimer. The type-I PKA holoenzyme contains RI subunits (RIa or RIb) and is primarily cytoplasmic, whereas the type-II holoenzyme contains RII subunits (RIIa or RIIb) and is associated with particulate subcellular fractions. Binding of cAMP to PKA R subunits releases the active C subunit (Ca, Cb or Cg) to phosphorylate nearby substrates [22] . Anchoring of PKA to an AKAP is achieved by the interaction of the R-subunit dimer with a 14-18 amino acid amphipathic a-helix region of AKAP [22] [23] [24] . Disruption PKA anchoring has been demonstrated experimentally using Ht31, a peptide that encompasses this amphipathic a helical region from an AKAP, AKAP-Lbc, which has a high affinity for the RII subunits of PKA. Although most AKAPs that have been characterized bind to RII subunits with high affinity, several AKAPs have been reported to interact specifically with RI [25] . D-AKAP1 and D-AKAP2 are examples of dual-specificity AKAPs that can anchor both types of R subunit [26] [27] [28] . AKAPs also have unique protein-lipid or protein-protein targeting domains that tether the PKA-AKAP complex to distinct subcellular locations to respond to local cAMP gradients [3, 22, 29, 30] . In support of this, Zhang et al. [14] used a genetically encoded PKAactivity reporter -A-kinase activity reporter (AKAR) -and demonstrated that, when PKA was tethered in the same complex as its substrate, the rate of phosphorylation was enhanced 3-4-fold. This provided evidence that, in response to cAMP, the release of C subunit from an AKAP complex would preferentially phosphorylate a local pool of substrate.
AKAP signaling complexes: mAKAPs
An important feature of AKAPs is their ability to interact with other signaling proteins in addition to PKA (Table 1) . These multienzyme complexes contain signal-termination enzymes, such as phosphatases and PDEs, and signaltransduction enzymes, such as kinases. Therefore, these enzymes can both upregulate and downregulate specific signaling pathways [3] . Currently, the focus of AKAP research is the identification of proteins that are associated with AKAPs. This provides candidate protein substrates for the anchored PKA. It also enables the study of how the interplay among AKAP-associated proteins can contribute to downstream biological response. Using this approach, it is becoming clear how enzymes of the mAKAP complex ( Figure 3 ) are involved in the regulation cardiac function. Immunoprecipitation studies from rat heart extracts demonstrated that PDE4D co-purified with both the RII subunit of PKA and mAKAP [20] . Additionally, it has been shown that the PDE4D3 isoform directly interacts with mAKAP and that it co-localizes with mAKAP at the nuclear membrane of cardiomyocytes [20] . The finding that both PDE4D3 and PKA are associated with mAKAP raised the possibility that the complex tightly regulates local cAMP concentrations and mAKAP-associated PKA activity. Indeed, inhibition of mAKAP-associated PDE4 activity enhanced the activity of the anchored PKA [20] . It has also been observed that phosphorylation of PDE4 by PKA enhanced its PDE activity [19, 31] . PDE4D3 is phosphorylated by PKA at two sites, Ser13 and Ser54. Phosphorylation at Ser54 results in a 2-3-fold enhancement in PDE activity [31] . Furthermore, experiments using the PKA inhibitor peptide (PKI) or a PKA-anchoring inhibitor peptide (Ht31) demonstrated that mAKAPassociated PKA phosphorylation caused a two-fold increase of PDE4D3 activity [20] . These observations suggested that mAKAP maintains a cAMP signaling complex in which PKA activity is attenuated by PDE The mAKAP complex at the nuclear membrane of cardiomyocytes brings together three cAMP effectors: PKA, PDE4D3 and Epac1. Each of these enzymes is activated at different concentrations of cAMP and there is interaction between them. As cAMP levels rise, activated PKA phosphorylates PDE4D3 in the complex at two distinct sites (double red arrow). Phosphorylation of Ser13 enhances the PDE affinity for mAKAP and phosphorylation of Ser54 increases the activity of PDE. This increase in activity depletes the local concentrations of cAMP and enables reformation of the inactive PKA holoenzyme. As cAMP levels fall, the Epac1-mediated inhibition of ERK5 pathway is blocked and the consequent ERK phosphorylation (red arrow) of PDE4D3 decreases the PDE activity, enabling accumulation of more cAMP. activity in a negative-feedback loop. Under basal conditions, mAKAP-associated PDE4D3 maintains local cAMP below the threshold level required to activate the anchored PKA. Upon hormonal stimulation, increased cAMP levels overcome the PDE activity, releasing active PKA C subunit from the AKAP complex. This leads to PKA phosphorylation of the tethered PDE4D3 on Ser54, thus increasing the local PDE activity. The subsequent increase in cAMP metabolism returns cAMP levels to basal, favouring the reformation of the PKA holoenzyme.
Although phosphorylation of Ser13 by PKA does not affect PDE activity, it enhances the affinity of PDE4D3 for mAKAP [32] . In addition, PKA phosphorylation has been shown to modulate protein-protein interactions within several other AKAP complexes [33, 34] . In the case of mAKAP, functional consequences of this type of regulation might be that PKA phosphorylates PDE4D3 at Ser13 and Ser54 in response to hormonal stimulation. If this is the case, PDE is drawn into the mAKAP complex and has increased activity, thereby decreasing the local levels of cAMP back to basal levels. Using modified versions of the AKAR2-PKA reporter, Dodge-Kafka et al. [15] examined whether this arrangement of PKA and PDE would generate local fluctuations in cAMP and pulses of compartmentalized PKA activity. The AKAR2-PKA activity reporter is sensitive to PDE activity in addition to PKA activity, thereby monitoring both the activation and termination of PKA signaling [4] . The modified AKAR2 reporters, AKAR-PKA and AKAR-PKA-PDE, bind PKA alone or PKA and PDE4D3, respectively [15] . Upon cAMP stimulation, cells that express AKAR-PKA reporter exhibited sustained elevation of FRET, indicating that the PKA associated with AKAR2 was activated. However, in cells that express the AKAR-PKA-PDE reporter, the FRET response was transient, presumably due to a drop in cAMP levels because the associated PDE activity increased [15] . This reporter serves as a model for the recruitment of PKA and PDE into a single complex to control localized cAMP gradients.
Other AKAPs that pair PKA with PDEs have been identified. PDE4D3 has been detected in the AKAP350 (AKAP450-Yotiao) complex at the centrosomal area of Sertoli cells [35] , and other members of the PDE family have been shown to associate with AKAP complexes [21] . For example, in T cells, PDE4A is associated with several AKAPs, including AKAP95, AKAP149 and MTG16b, which has also been shown to target another PDE, PDE7A [21] . Although the functional implications of these interactions have not been fully investigated, the activity of these PDEs might be controlled by AKAPassociated kinases and phosphatases. Protein phosphatases, such as those found in AKAP350 and mAKAP complexes, might also contribute to regulation of local cAMP gradients by counterbalancing PKA phosphorylation events [36, 37] .
PDE activity can be regulated by other enzymes, such as members of the extracellular-signal-regulated kinase (ERK) family, that might also be present in these cAMPsensitive complexes [19, 38, 39] . Phosphorylation of long isoforms of PDE4 such as PDE4D3 by ERK2 inhibits activity and results in an increase level of intracellular cAMP [39, 40] . Therefore, an alternative feedback system might exist in which activation of the ERK-signaling pathway leads to inhibition of PDE activity and, hence, an increase in cAMP levels. This would, in turn, lead to PKA activation. Dodge-Kafka et al. [15] demonstrated that upstream stimulation of ERK leads to a sustained rather that a transient AKAP-PKA-PDE FRET signal. Furthermore, activation of ERK signaling in cardiomyocytes reduced the mAKAP-associated PDE activity [15] . Within the mAKAP complex, active ERK can suppress PDE activity, leading to an increase in anchored-PKA activity.
cAMP differentially regulates ERK signaling pathways in a manner that depends on cell type and growth condition [41] [42] [43] . In cultured rat neonatal ventriculocytes (RNVs), stimulation of cAMP synthesis prevented activation of ERK5 that is present in mAKAP complexes [15] . Inhibition of PKA did not reverse this effect, suggesting that a different cAMP effector was responsible. Epac1 co-precipitated with mAKAP from rat heart extract and was also present at the perinuclear membranes of hypertrophic RNVs, suggesting that it might be the cAMP effector preventing activation of ERK5 [15] . Biochemical data demonstrated that Epac1 is associated with the mAKAP complex by a direct interaction with PDE4D3. Furthermore, the Epac1-selective cAMP analog 8-CPT-2 0 -O-Me-cAMP suppressed stimulation of mAKAP-associated ERK5 activity in RNVs [15, 44] . Epac1 is a cAMPdependent guanine-nucleotide exchange factor (GEF) for the small RAS-like GTPase proteins repressor-activator proteins Rap1 and Rap2 [45] [46] [47] . Constitutively active RapGAP (a GTPase-activating protein that attenuates Rap1 activity) prevented the effect of cAMP on mAKAPassociated ERK5 activity, suggesting that Epac1 mediates its effects on ERK5 through Rap1 [15] .
Local cAMP levels and cardiac function Cardiac hypertrophy, an enlargement of heart-muscle cells, occurs in response to either exercise (physiological hypertrophy) or chronic hypertension (pathological hypertrophy) [48, 49] . Physiological hypertrophy is beneficial because it enhances cardiac output to meet the increased metabolic demands of the body, whereas pathological hypertrophy is a major risk factor in the progression of heart failure [48, 49] . A model for cardiac hypertrophy is provided by the treatment of RNVs with hypertrophic agonists. One such agent -leukemia inhibitory factor (LIF) -increases ERK5 activity in these cells [50] . MEK5, a dominant negative form of the activator of the MAPkinase ERK5, blocked LIF-induced 'eccentric hypertrophy', which is an increase in myofibril length. In addition, the expression of constitutively active MEK5 in the cardiac tissue of transgenic mice resulted in eccentric hypertrophy and heart failure [50] . Both inhibition of ERK-kinase activity and activation of Epac1 by 8-CPT-2 0 -O-Me-cAMP blocked the ability of LIF to increase the size of RNVs [15] . This was also partially blocked by PDE4 inhibition [15] . Clearly, the enzymes that make up the mAKAP complex have a role in facilitating LIF-induced hypertrophy. Indeed, knockdown by RNA interference (RNAi) of mAKAP suppressed the ability of LIF to induce hypertrophy in RNVs. This phenomenon was rescued when a form of mAKAP resistant to short hairpin RNA (shRNA) was expressed in the knockdown cells [15] . Furthermore, overexpression of a fragment of the mAKAP targeting sequence disrupted the perinuclear targeting of mAKAP and blocked the LIF-induced increase in cell size [15] . Thus, mAKAP targets cAMP-responsive enzymes to the perinuclear region of the cell to respond to upstream signals and modulate their effect on cardiomyocyte size.
The importance of local cAMP levels in cardiac function is also highlighted by a recent study in which PDE4D-deficient mice have developed age-related cardiomyopathy, exercise-induced arrhythmias and heart failure [51] . Total cellular cAMP levels were similar in knockout and wildtype mice; however, there seemed to be differences within cellular microenvironments. In the Z-lines of cardiomyocytes from PDE4D-deficient mice, cAMP levels were increased compared with those observed in wild-type mice. PDE4D-deficient mice also showed enhanced PKA phosphorylation of the cardiac ryanodine receptor (RY 2 receptor), and these hyperphosphorylated, 'leaky' RY 2 receptors exhibited defects in function. This finding is consistent with changes that were observed in human failing hearts. PDE4D3 is a component of a RY 2 receptor complex in mouse and human cardiac tissue. Both levels of PDE4D3 bound to RY 2 receptor and RY 2 receptorassociated PDE4 activity were reduced to a similar degree in failing human and PDE4D-deficient mouse hearts. Importantly, there was an improvement in cardiac function that was observed in PDE4D-deficient mice in which the RY 2 receptors could not be phosphorylated by PKA (RyR2-S2808A) [51] . Given that inhibitors of PDE4 are being developed as therapeutic agents for several chronic diseases, understanding the role of PDEs and regulation of local cAMP levels in the heart is essential. The role of distinct PDE isozymes in regulating local cAMP levels in neonatal rat cardiomyocytes was investigated using a cAMP biosensor that consists of R and C subunits of PKA that were labeled with fluorophores [7] . In this study, PDE3 and PDE4 were shown to have differential effects on resting cAMP levels and cAMP generated by the stimulation of b-adrenergic receptors. Furthermore, each PDE isoform was found in distinct subcellular locations in cultured cardiac myocytes, indicating that distinct pools of PDEs might have a role in the control of specific, localized pools of cAMP.
Local cAMP levels and lipolysis
Regulation of distinct pools of cAMP at specific sites within the cell is likely to be an important process in many other cell types. Historically, cAMP signaling was identified as a consequence of studies on lipolysis and insulin action. Additional understanding of the intricate balance of fuel storage and utilization in adipose-tissue metabolism suggests a probable role for AKAPs. Adipocytes are the main site of triglyceride storage in mammals [52, 53] . Hormonal stimulation of b-adrenergic receptors on these cells increases cAMP levels and PKA activity, resulting in lipolysis of the stored triglycerides. PKA stimulates lipolysis by phosphorylating the hormone-sensitive lipase (HSL) and perilipin [54, 55] . PKA also phosphorylates and activates PDE3B, reducing cAMP levels and, thereby, bringing PKA activity back to basal levels [56] . Insulin stimulation also activates PDE3B in a phosphatidylinositol-3-kinase (PI3-kinase)-and protein-kinase-B (PKB)-dependent manner, thereby reducing lipolysis [53, 57, 58] . Chronic insulin treatment of adipocytes, however, has been reported to increase isoproterenolinduced cAMP generation [59] . The effect of insulin treatment on cAMP-induced activation of PKA was measured using the PKA-activity reporter AKAR2 in 3T3-L1 adipocytes [4] . Chronic insulin treatment did not change basal AKAR2 phosphorylation, but the PKA response to isoproterenol was delayed. By contrast, there was no insulin-induced delay in PKA phosphorylation when cAMP levels were increased either by forskolin treatment or cAMP uncaging. This suggested that the insulin-induced delay was specific for a b-adrenergicassociated pool of PKA [4] . The RIIb subunit of PKA was associated with the b-adrenergic receptor in immunoprecipitates from 3T3-L1 adipocytes and maintained or slightly increased after isoproterenol treatment. Pretreatment of 3T3-L1 adipocytes with insulin, however, led to a reduction of this association. Importantly, use of the AKAP-PKA-anchoring inhibitor peptide, Ht31, suggested that the PKA is coupled to the b-adrenergic receptor through direct interaction with an AKAP [4] . In adipocytes, chronic hyperinsulinemia might weaken the association of an AKAP-anchored PKA to the b-adrenergic receptor, and activation of the receptor leads to disruption of the PKA-b-adrenergic-receptor complex, possibly through PKA phosphorylation mechanisms. AKAP79-150 and Gravin are possible candidates to mediate the interaction with the b-adrenergic receptor [60] [61] [62] [63] .
Concluding remarks
AKAPs contribute to the specificity of cAMP signaling by recruiting PKA and other effector proteins to a given subcellular environment where the activation of precise enzyme combinations mediates the required biological outcome. Each effector has a distinct threshold for activation by cAMP. The mAKAP complex in the heart coordinates three enzymes: PKA, PDE4D3 and Epac1, to ensure the appropriate response at the local cAMP level as this ubiquitous second messenger is increased or decreased. Recently, it has been shown that a growing number of AKAPs also incorporate PDEs into the complex for fine-tuning of the cAMP gradient within a microdomain. This provides an additional level of sophistication that enables spatial and temporal control of cAMP flux.
Another potential function for these extended AKAP-PDE signaling complexes might be to suppress bursts of cAMP synthesis that emanate from receptor-Gprotein-adenylyl-cyclase complexes at the plasma membrane. This might be particularly relevant for the adenylyl cyclase isoforms AC5 and AC6 that are inhibited by PKA phosphorylation. [5, 64, 65] . If this latter configuration of signaling enzymes exists, it would provide an additional negative-feedback mechanism to synchronize the ebb and flow of cAMP as it diffuses across the cell.
Generation of the ubiquitous second messenger cAMP in response to many different extracellular stimuli requires tight regulation, but flexible, downstream Review machinery to ensure the appropriate cellular response. A growing body of work on the role that AKAPs have in the heart and in other tissues provides evidence that these multifunctional scaffolding proteins facilitate the fidelity of cAMP signaling. This tight control of cAMP signaling is clearly important in the maintenance of a healthy state, whereas the loss of this regulation might initiate diseases. Future translational studies will apply what we have learned about the cellular role of AKAPs to address the etiological questions of heart disease and other chronic illnesses (Box 1).
